Kantarjian H, Ajani J A, Karlin D A
Oncology. 1985;42(2):69-71. doi: 10.1159/000226003.
A phase II study of cis-diaminodichloroplatinum (II) (cis-DDP) was carried out in 55 patients with advanced adenocarcinoma of the upper gastrointestinal tract. The drug was given at a dose of 100 mg/m2 i.v. over 2h every 3-4 weeks, with hydration and mannitol diuresis. There were 3 partial responses (6%) among 51 evaluable patients (esophagus 12, stomach 16, pancreas 14, liver 6, and biliary 3). Toxicity was moderate with cumulative nephrotoxicity being the most serious side effect. Myelosuppression was noted in 25% of patients, all having had prior therapy with mitomycin C and nitrosoureas. Activity of cis-DDP as a single agent against adenocarcinoma of the upper gastrointestinal tract in our patient population was minimal.
对55例晚期上消化道腺癌患者进行了顺二氯二氨铂（II）（顺铂）的II期研究。每3 - 4周静脉注射给药一次，剂量为100mg/m²，持续2小时，同时进行水化和甘露醇利尿。在51例可评估患者（食管12例、胃16例、胰腺14例、肝脏6例和胆管3例）中，有3例部分缓解（6%）。毒性为中度，累积肾毒性是最严重的副作用。25%的患者出现骨髓抑制，所有患者此前均接受过丝裂霉素C和亚硝基脲治疗。在我们的患者群体中，顺铂作为单一药物对上消化道腺癌的活性极小。
